Champions Oncology

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Champions Oncology reports Q4 rebound, eyes revenue growth in 2025

Champions Oncology navigated challenges to achieve improved financial performance in Q4. The company is well-positioned with no debt and a cash-neutral strategy for 2025. Management's confidence in long-term prospects signals growth potential.

Champions Oncology (CSBR) reports robust Q1 earnings and growth outlook

Champions Oncology (CSBR) delivered a strong performance in Q1 2025, with revenue surpassing $14 million and notable margin improvements. Despite challenges faced in the past, the company has demonstrated resilience and improvement, positioning itself for future growth. Optimism from management and strategic initiatives highlight a promising outlook for Champions Oncology.

Champions Oncology excels in Q2 2025, eyes new revenue streams

Champions Oncology's Q2 2025 showcased robust financial performance, driven by revenue growth, margin improvement, and cost control measures. While facing challenges in capital needs and competitive pressures, the company's strong fundamentals and strategic initiatives position it well for future opportunities. By leveraging its core strengths and exploring new revenue streams, Champions Oncology aims to sustain its growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2022, on Tuesday, March 15, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2022

HACKENSACK, NJ / ACCESSWIRE / February 15, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today a co-development partnership with GigaMune. The partnership will combine Champions' novel Autologous Tumor Infiltrating Lymphocyte (TIL) platform with GigaMune's T Cell Receptor (TCR) Discovery platform to accelerate the development of next generation T cell therapies and cancer diagnostics, through the identification of novel TCR sequences.

Champions Oncology Announces a Partnership with GigaMune to Discover Novel Tumor-Reactive T Cell Receptors

HACKENSACK, NJ / ACCESSWIRE / January 20, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today a therapeutic co-development partnership with Fannin Innovation Studio. The partnership will combine novel therapeutic targets identified within Champions' Lumin platform with Fannin's Therapeutic Raptamer platform to develop next generation Raptamer Drug Conjugates (RDC's).

Champions Oncology Announces a Partnership with Fannin Innovation to Jointly Develop Therapeutic Raptamer Drug Conjugates

HACKENSACK, NJ / ACCESSWIRE / January 4, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today a therapeutic development partnership with Alloy Therapeutics. The partnership will combine novel therapeutic targets identified within Champions' Lumin platform with Alloy's fully-integrated in vivo and in vitro antibody discovery, optimization, and lead development services platform to develop antibodies used in the development of next generation Antibody Drug Conjugates (ADCs).

Champions Oncology Announces a Partnership with Alloy Therapeutics to Develop Therapeutic Monoclonal Antibodies for Use in ADC Programs

Champions Oncology Inc.'s (CSBR) CEO Ronnie Morris on Q2 2022 Results - Earnings Call Transcript

Reported income from operations of $263,000 HACKENSACK, NJ / ACCESSWIRE / December 13, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, today announced its financial results for its second quarter of fiscal 2022, ended October 31, 2021. Second Quarter and Recent Highlights: Record quarterly revenue of $11.8 million, an increase of 17% year over year Reported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $743,000 Gross margin improved to 52% Ronnie Morris, CEO of Champions, commented, "We had another quarter of milestone achievements for the Company as we saw strong operating results in our research service business and continued to expand the customer base of our SaaS Lumin platform.

Champions Oncology Reports Record Quarterly Revenue of $11.8 Million

HACKENSACK, NJ / ACCESSWIRE / December 6, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), leaders in transformative technology solutions utilized in oncology drug discovery and development will report its financial and operational results for the second quarter ended October 31, 2021, on Monday, December 13, 2021, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Champions Oncology to Announce Second Quarter Financial Results on Monday, December 13, 2021

HACKENSACK, NJ / ACCESSWIRE / October 20, 2021 / Champions Oncology (NASDAQ:CSBR), a technology-enabled research organization announced the opening of a European laboratory located in the renowned OpenZone Life Sciences Campus in Bresso, Italy, on the doorstep of Milan. After launching preclinical and clinical GCLP-compliant biomarker services in 2019, Champions Oncology has rapidly grown to be a leader in the industry by providing scientific expertise, unparalleled quality, and innovative data analytics.

Champions Oncology Expands Global Biomarker Capabilities with Opening of European Laboratory at OpenZone Life Sciences Campus

Champions Oncology's (CSBR) CEO Ronnie Morris on Q1 FY2022 Results - Earnings Call Transcript

HACKENSACK, NJ / ACCESSWIRE / September 13, 2021 / Champions Oncology, Inc. (Nasdaq:CSBR), leaders in transformative technology solutions utilized in drug discovery and development, today announced its financial results for its first quarter of fiscal 2022, ended July 31, 2021. First Quarter and Recent Highlights: Record quarterly revenue of $11.3 million, an increase of 18% year over year Reported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $422,000 Validated 6 therapeutic discovery targets Ronnie Morris, CEO of Champions, commented, "On our year-end earnings call, we outlined the transformative strategic vision for Champions with the expansion of our services to include a Software as a Service ("SaaS") business and therapeutic target discovery platform.

Champions Oncology Reports Record Quarterly Revenue of $11.3 Million

Champions Oncology, Inc. (CSBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Champions Oncology, Inc. (CSBR) Reports Next Week: What You Should Expect

HACKENSACK, NJ / ACCESSWIRE / September 2, 2021 / Champions Oncology, Inc. (CSBR), leaders in transformative technology solutionsutilized in oncology drug discovery and development will report its financial and operational results for the first quarter ended July 31, 2021, on Monday, September 13, 2021, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Champions Oncology to Announce First Quarter Financial Results on Monday, September 13, 2021

HACKENSACK, NJ / ACCESSWIRE / July 26, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today an expansion of its corporate strategy as they unveil their entry into the drug discovery and development space. Champions is organized as a dynamic ecosystem of business units centered around a world leading oncology research center that is based off a unique & proprietary set of data and experimental platforms.

Champions Oncology Announces an Expanded Corporate Strategy to Include Drug Discovery and Development

Record Annual Revenue of $41 Million HACKENSACK, NJ / ACCESSWIRE / July 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in creating transformative technology solutions to be utilized in drug discovery and development, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2021. Fourth Quarter and Fiscal Year 2021 Financial and Recent Business Highlights: Record annual revenue of $41.0 million, an increase of 28% year-over-year Developed in house computational target discovery expertise to discover novel therapeutic targets Continued expansion of our Lumin SaaS platform Ronnie Morris, CEO of Champions, commented, "Our year was highlighted by new strategic initiatives that have the potential to be transformative for Champions.

Champions Oncology Reports Quarterly Revenue of $10.6 Million

HACKENSACK, NJ / ACCESSWIRE / July 14, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, today announced it will report its financial and operational results for the fourth quarter ended April 30, 2021, on Thursday, July 22, 2021, before market open. The company will host a conference call to discuss the results that day at 8:30 a.m.

Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 22, 2021

HACKENSACK, NJ / ACCESSWIRE / June 15, 2021 / Champions Oncology (NASDAQ:CSBR), a technology-enabled research organization announced today that they have entered into a strategic partnership with BGI Americas. Through this partnership, BGI will now have access to Champions' Lumin Bioinformatics platform, a revolutionary data interpretation tool, to display and deliver proteomics data to their clients.

Champions Oncology and BGI Americas Announce a Strategic Partnership to Provide Mass Spectrometry Proteomics, Metabolomics, and Multi-Omic Data Analysis Solutions

Champions Oncology, Inc. (CSBR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Champions Oncology, Inc. (CSBR) Upgraded to Buy: What Does It Mean for the Stock?

Acme United

CF Bankshares Inc

Escalade

Meridian Corp

Security National Financial

The markets keep going up as new stimulus spending and the massive new infrastructure bill hit. These micro-cap stocks are bargains.

7 Micro-Cap Stocks to Buy That Are Shining Right Now

Champions Oncology, Inc. (CSBR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Champions Oncology, Inc. (CSBR): Can Its 15.3% Jump Turn into More Strength?

HACKENSACK, NJ / ACCESSWIRE / March 11, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery and development through data-driven research strategies and innovative pharmacology, biomarker and data platforms, today announced its financial results for the third fiscal quarter ended January 31, 2021. Third Quarter and Recent Highlights: Delivered record quarterly revenue of $10.8 million, an increase of 20% year over year Reported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $1.3 million Expanded Lumin Bioinformatics proprietary SaaS platform with proteomic module integration Ronnie Morris, CEO of Champions, commented, "We are pleased with our third quarter results and we continue to execute our long term strategy of investing in the development of new products and services to increase our revenue streams.

Champions Oncology Reports Record Quarterly Revenue of $10.8 Million

HACKENSACK, NJ / ACCESSWIRE / March 5, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, today announced it will report its financial and operational results for the third quarter ended January 31, 2021, on Thursday, March 11, 2021, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m.

Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 11, 2021

Analysts Estimate Champions Oncology, Inc. (CSBR) to Report a Decline in Earnings: What to Look Out for

HACKENSACK, NJ / ACCESSWIRE / January 19, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology company that is transforming drug discovery and development through data-driven research strategies, announced today a partnership with Code Ocean to expand the functionality of its SaaS program, Lumin Bioinformatics. The partnership between Champions and Code Ocean will focus on enhancements involved in data integration and sharing workflows within the Lumin platform.

Champions Oncology Announces Partnership with Code Ocean to Expand the Functionality of Lumin Bioinformatics

HACKENSACK, NJ / ACCESSWIRE / January 5, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology company that is transforming drug discovery and development through data-driven research strategies, announced today the expansion of its SaaS program, Lumin Bioinformatics. Since its launch, Champions has been adding to the data and functionality housed within Lumin, which now features 20,000+ datasets including rare and valuable quantitative phospho-proteomics.

Champions Oncology Announces the Expansion of Lumin Bioinformatics: Now Featuring a Highly Valuable Set of Proteomic Data and Analytics

Champions Oncology (CSBR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

News for Champions Oncology Stock (CSBR)